Your browser doesn't support javascript.
loading
: 20 | 50 | 100
1 - 20 de 26
1.
Scand J Surg ; 110(1): 105-109, 2021 Mar.
Article En | MEDLINE | ID: mdl-31830877

BACKGROUND AND AIM: Talc poudrage has been used since many years for sclerosing chronic pleural effusion. Several reports have shown good results managing chronic seromas after breast, vascular, and incisional hernia surgeries. The purpose of this study is to determine the utility of talc seromadesis for the management of chronic seromas after incisional hernia surgery. MATERIALS AND METHODS: Multicentric prospective observational study including patients diagnosed of chronic seromas after incisional hernia surgery. Under local anesthesia and ultrasonographic control, two percutaneous trocars were placed in the seroma, washing the seroma cavity with 0.9% saline solution and aspirating the remaining liquid. A sample of 4 g of talcum powder was introduced in the seroma cavity, and a 15-F drain was left in place. Patients were followed each week during at least 4 weeks after drainage removal. RESULTS: Between January 2013 and December 2016, a total of six patients were enrolled in the study. Talc poudrage was performed without any complications. Drains were pulled out in a mean time of 3 (range: 2-4) weeks. One case of the chronic seromas was efficiently sclerosed with talc without recurrence in time. In three cases, the seroma recurred, and the final solution was surgical decortication of the seroma. In the other two cases, seroma also recurred and were managed with instillation of ethanol and iodine povidone. CONCLUSION: In our experience, the management of chronic seromas after incisional hernia repair with talc seromadesis is ineffective and is associated with a high rate of seroma recurrence.


Incisional Hernia/surgery , Postoperative Complications/drug therapy , Seroma/drug therapy , Aged , Drainage , Female , Humans , Male , Middle Aged , Prospective Studies , Talc/administration & dosage , Treatment Failure
2.
Transplant Proc ; 43(3): 751-2, 2011 Apr.
Article En | MEDLINE | ID: mdl-21486591

The incidence of fungal complications is frequent among liver transplanted subjects. Between March 1986 and June 2009, we performed 670 liver transplants in 593 patients, including 61% males and an overall average age of 46. The incidence of arterial complications in our center was 5.3% (32/593 patients), including 24 (75%) thromboses, 5 (16%) pseudoaneurysms, 2 anastomotic stenoses, and 1 an iliac graft rupture owing to a mycotic aneurysm. Four patients presented arterial complications associated with Aspergillus sp. Three of them were males of mean age 50 years and 3 had an acute rejection episode. Immunosuppression was cyclosporine (CsA), steroids, and azathioprine. Four arterial complications were diagnosed: 2 thromboses and 2 pseudoaneurysm ruptures. Two patients presented biliary complications associated with the arterial complication and Aspergillus infection. Treatment was expectant in 1 patient, interventional radiology in an other, and retransplantation in the other 2. All patients infected with Aspergillus sp. diad of sepsis and multiorgan failure. Arterial complications posttransplant associated with infection by Aspergillus sp., can be an important cause of retransplantation, sepsis and death.


Arteries/pathology , Aspergillosis/etiology , Liver Transplantation/adverse effects , Vascular Diseases/etiology , Female , Humans , Male , Middle Aged
3.
Transplant Proc ; 41(3): 1067-9, 2009 Apr.
Article En | MEDLINE | ID: mdl-19376429

BACKGROUND: Hepatocellular carcinoma (HCC) represents one of the most common malignancies globally, accounting for nearly one million new cases per year. Although the treatment of extrahepatic metastases from primary liver tumors is essentially palliative, a solitary metastasis from such tumors offers a possibility of cure by surgical resection. The adrenal gland is an uncommon site for metastasis from primary liver tumors. METHODS: We report a liver transplantation case of HCC and hepatitis B virus in a 23-year-old man with an excellent postoperative result. However, because an increased alpha-fetoprotein was evident and complete radiologic and blood tests were performed, all of which were normal. Three years posttransplantation, a right adrenal mass was identified by CT. PAAF was performed as well as adrenalectomy for a solitary adrenal metastasis from hepatocellular carcinoma. RESULTS: The patient underwent adrenalectomy for the right adrenal metastasis at 3 years following liver transplantation for HCC. He is presently alive and disease-free 24 months after adrenalectomy. CONCLUSION: Carefully selected patients with solitary metastasis from HCC may be considered for resection.


Adrenal Gland Neoplasms/secondary , Adrenal Gland Neoplasms/surgery , Adrenalectomy , Carcinoma, Hepatocellular/pathology , Carcinoma, Hepatocellular/surgery , Liver Neoplasms/pathology , Liver Neoplasms/surgery , Liver Transplantation/adverse effects , Liver Transplantation/pathology , Adrenal Gland Neoplasms/diagnostic imaging , Adult , Carcinoma, Hepatocellular/mortality , Everolimus , Follow-Up Studies , Humans , Immunosuppressive Agents , Liver Neoplasms/immunology , Liver Transplantation/mortality , Neoplasm Metastasis , Sirolimus/analogs & derivatives , Sirolimus/therapeutic use , Survival Analysis , Time Factors , Tomography, X-Ray Computed , Treatment Outcome , Young Adult
4.
Transplant Proc ; 35(5): 1850-1, 2003 Aug.
Article En | MEDLINE | ID: mdl-12962821

INTRODUCTION: Prophylaxis using high-dose intravenous anti-HBV immune globulin (HBIG) is effective to prevent reinfection due to hepatitis B virus (HBV) after orthotopic liver transplantation (OLT). However, this treatment is expensive and intravenous administration is difficult during outpatient care. Our aim was to assess the effectiveness of low-dose intramuscular HBIG to prevent HBV reinfection after OLT. PATIENTS: Six patients (all men, mean age 41 years, negative HBV DNA without hepatotropic virus coinfection) were transplanted in our institution due to HBV cirrhosis and included in a prospective noncomparative study. Intramuscular HBIG (2000 IU) was administered during the anhepatic phase of OLT, followed by daily 2000 IU doses for 7 days and then monthly. HBV antibody titers were measured every month. Reinfection was defined as the recurrence of surface HBV antigen in serum after transplantation. RESULTS: After 1 year follow-up, none of the six patients had detectable HBV surface antigen and the liver biopsies were normal in all cases. Using 2000 IU, anti-HBs levels were: 880+/-356 IU/L at 1 month, 191+/-123 at 6 months, and 225+/-49 after 1 year. In all cases anti-HBs titers were above 100 IU/L during the follow-up. CONCLUSIONS: Monthly administration of low-dose (2000 IU) intramuscular HBIG effectively prevents recurrence of HBV infection as well as attains a protective level of anti-HBs antibodies (over 100 IU/L) for at least the first year after transplantation.


Hepatitis B/prevention & control , Hepatitis B/surgery , Immunoglobulins/therapeutic use , Liver Transplantation , Adult , DNA, Viral/blood , Hepatitis B/immunology , Hepatitis B Antibodies/blood , Hepatitis B virus/isolation & purification , Humans , Immunization, Passive , Recurrence
5.
Transplant Proc ; 35(5): 1896-7, 2003 Aug.
Article En | MEDLINE | ID: mdl-12962838

INTRODUCTION: De novo tumors (DNTs) are the leading cause of late death among liver transplant recipients with an incidence of 5% to 15%, which is significantly greater than the general population. In this retrospective study, we compared this complication in liver transplant recipients to sex- and age-matched controls. PATIENTS: Among 410 patients who received liver allografts between March 1986 and December 2000, 32 (7.8%) developed a DNT. Epidermoid tumors were the most frequent histologic lineage. A complete response was observed in 19 patients (59.4%), a partial response in eight (25%), and no response in five (15%). Survival was lower among liver transplant recipients than controls, a difference that was statistically significant. Treatment consisted of surgery in 76.7%, radiotherapy in 16.7%, chemotherapy in 13.3%, and reduction of immunosuppression in 10%. RESULTS: The mean survival time in transplant patients of 122.97 months (95% CI; range 98-147 months) was significantly shorter than controls, 156.5 months (95% CI; range 141-171 months). About 50% of patients were smokers (active or ex-smokers), compared to 20.7% of controls (P=.049). Significant differences were also found when the three subgroups (smokers, previous smokers, and nonsmokers) were analyzed separately (P=.013). Patients were smokers (active or nonactive) among 45% of cases of skin tumors; 60% of hematological tumors; 71.4% of epidermoids; and 33% of sarcomas. CONCLUSIONS: DNTs, a complication of long-term immunosuppression in patients after liver transplantation, most frequently presented as skin tumors and PTLD. Occurrence of a DNT was an adverse prognostic factor for survival. Smoking represents an independent risk factor for these tumors.


Liver Neoplasms/mortality , Neoplasms/epidemiology , Adult , Aged , Case-Control Studies , Cause of Death , Follow-Up Studies , Humans , Middle Aged , Neoplasms/mortality , Postoperative Complications/mortality , Retrospective Studies , Survival Analysis , Time Factors , Transplantation, Homologous
10.
Clin Genet ; 60(1): 52-7, 2001 Jul.
Article En | MEDLINE | ID: mdl-11531970

We have studied the role of three polymorphic genes of the renin-angiotensin system (RAS) as independent risk factors for myocardial infarction (MI) and their correlation with three of the major coronary risk factors: serum cholesterol (CH), hypertension (HT) and smoking (SM). A population of 392 men was genotyped for the M235T polymorphism of the angiotensinogen (AGT) gene, the insertion/deletion of the angiotensin-converting enzyme (ACE) and the all66c of the angiotensin-II type 1 receptor (AT1R), by means of polymerase chain reaction (PCR) and restriction enzyme analysis. It was observed that the T allele frequency increased significantly in the MI with HT, CH, and SM subgroup (0.58 vs 0.31) (p<0.01). In contrast, the M allele frequency was higher in the MI without HT, CH, and SM (0.69 vs 0.42) (p<0.01). A strong association between the MM genotype and MI (p<0.001, odds ratio=4.29, confidence interval=1.95-9.42) was found when age-matched MM control subjects were compared to MI individuals with none of the other known major coronary risk factors. Futhermore, subjects with the MM genotype showed a significantly higher plasma renin activity (PRA) profile than those with the TT genotype (p<0.001). It can be concluded that the M allele is an independent risk factor for MI and the T allele modified the risk when other major risk factors are present.


Alleles , Angiotensinogen/genetics , Myocardial Infarction/genetics , Adult , Amino Acid Substitution , Cholesterol/blood , DNA/genetics , Gene Frequency , Genotype , Humans , Hypertension/complications , Male , Middle Aged , Myocardial Infarction/etiology , Peptidyl-Dipeptidase A/genetics , Polymorphism, Genetic , Receptor, Angiotensin, Type 1 , Receptor, Angiotensin, Type 2 , Receptors, Angiotensin/genetics , Renin/blood , Renin-Angiotensin System/genetics , Risk Factors , Smoking/adverse effects
11.
Nat Genet ; 25(1): 91-5, 2000 May.
Article En | MEDLINE | ID: mdl-10802664

Specialized collagens and small leucine-rich proteoglycans (SLRPs) interact to produce the transparent corneal structure. In cornea plana, the forward convex curvature is flattened, leading to a decrease in refraction. A more severe, recessively inherited form (CNA2; MIM 217300) and a milder, dominantly inherited form (CNA1; MIM 121400) exist. CNA2 is a rare disorder with a worldwide distribution, but a high prevalence in the Finnish population. The gene mutated in CNA2 was assigned by linkage analysis to 12q (refs 4, 5), where there is a cluster of several SLRP genes. We cloned two additional SLRP genes highly expressed in cornea: KERA (encoding keratocan) in 12q and OGN (encoding osteoglycin) in 9q. Here we report mutations in KERA in 47 CNA2 patients: 46 Finnish patients are homozygous for a founder missense mutation, leading to the substitution of a highly conserved amino acid; and one American patient is homozygous for a mutation leading to a premature stop codon that truncates the KERA protein. Our data establish that mutations in KERA cause CNA2. CNA1 patients had no mutations in these proteoglycan genes.


Cornea/abnormalities , Corneal Diseases/genetics , Eye Proteins/genetics , Eye Proteins/metabolism , Mutation/genetics , Proteoglycans/genetics , Proteoglycans/metabolism , Amino Acid Sequence , Collagen/metabolism , Cornea/metabolism , Founder Effect , Humans , Leucine/metabolism , Molecular Sequence Data , Physical Chromosome Mapping , Sequence Alignment
12.
Cir. Esp. (Ed. impr.) ; 67(4): 400-402, abr. 2000. ilus
Article Es | IBECS | ID: ibc-3760

La causa más frecuente de hipertensión portal segmentaria es la trombosis aislada de la vena esplénica, generalmente asociada a pancreatitis crónica o a cáncer de páncreas. Presentamos el caso de un paciente con episodios repetidos de hemorragia digestiva alta por varices esofagogástricas secundarias a hipertensión portal segmentaria producidos por la compresión de un quiste verdadero de páncreas sobre la vena esplénica, lo que constituye una causa no descrita hasta el momento. La esplenectomía más pancreatectomía distal realizada reduce el flujo venoso de las colaterales proporcionando la curación en más del 90 por ciento de los casos (AU)


Male , Middle Aged , Humans , Splenic Vein/physiopathology , Splenic Vein/pathology , Splenectomy , Pancreatectomy , Pancreatic Cyst/surgery , Pancreatic Cyst/complications , Pancreatic Cyst/diagnosis , Hypertension, Portal/complications , Hypertension, Portal/etiology , Pancreatic Ducts , Pancreatic Fistula/etiology , Pancreatic Fistula/surgery , Pancreatic Fistula , Angiography/methods , Angiography , Splenomegaly/complications , Splenomegaly/diagnosis , Splenomegaly/therapy , Tomography, Emission-Computed , Angiography
13.
Atherosclerosis ; 145(2): 293-300, 1999 Aug.
Article En | MEDLINE | ID: mdl-10488956

We analyzed the evolution with age of the frequencies of the I/D polymorphism of the angiotensin I-converting enzyme (ACE), a1166c of the angiotensin II AT1 receptor (AT1R), M235T of the angiotensinogen (AGT) and A225V of their methylenetetrahydrofolate reductase (MTHFR) gene in a healthy (H) population and the subsequent comparison to age- and sex-matched groups of myocardial infarction (MI) subjects. A total of 472 H subjects were divided into three groups < 30, 30-55 and > 55 years old and 277 individuals with MI into two groups 30-55 and > 55 years old. The evolution with age showed that the AGT M allele (P < 0.001) and the MTHFR V allele (P < 0.05) frequency decreased with age in H men. The comparison between healthy and MI groups showed that the MM genotype frequency increased in MI men > 55 years (OR =4.16; 95% CI; 1.72-10.1) The cc genotype showed a similar behaviour (OR = 3.96; 95% CI; 1.21-12.9). In men, all the combinations with MM genotype presented a high risk, with OR values between 1.10 and 7.22. In women, the cc genotype increased in the MI > 55 group (OR = 6.66; 95% CI; 2.02-21.9). All the combinations with the cc genotype showed OR values between 1.71 and 13.3. The MM genotype in men and cc genotype in men and women, are independent risk factors for MI. We propose that the study of the allele frequency evolution in an H population at different ages is essential to determine risk factors for MI in case-control studies, since data from isolated age-matched groups can be misinterpreted.


Myocardial Infarction/genetics , Oxidoreductases Acting on CH-NH Group Donors/genetics , Renin-Angiotensin System/genetics , Adult , Aged , Alleles , Angiotensinogen/blood , Angiotensinogen/genetics , Case-Control Studies , DNA/analysis , DNA Transposable Elements , Female , Gene Frequency , Genotype , Humans , Male , Methylenetetrahydrofolate Reductase (NADPH2) , Middle Aged , Myocardial Infarction/physiopathology , Oxidoreductases Acting on CH-NH Group Donors/blood , Peptidyl-Dipeptidase A/blood , Peptidyl-Dipeptidase A/genetics , Polymerase Chain Reaction , Receptor, Angiotensin, Type 1 , Receptor, Angiotensin, Type 2 , Receptors, Angiotensin/blood , Receptors, Angiotensin/genetics
16.
Nat Genet ; 15(4): 393-6, 1997 Apr.
Article En | MEDLINE | ID: mdl-9090386

Progressive myoclonus epilepsy of Unverricht-Lundborg type (EPM1; MIM 254800) is an autosomal recessive disorder that occurs with a low frequency in many populations but is more common in Finland and the Mediterranean region. It is characterized by stimulus-sensitive myoclonus and tonic-clonic seizures with onset at age 6-15 years, typical electroencephalographic abnormalities and a variable rate of progression between and within families. Following the initial mapping of the EPM1 gene to chromosome 21 (ref. 6) and the refinement of the critical region to a small interval, positional cloning identified the gene encoding cystatin B (CST6), a cysteine protease inhibitor, as the gene underlying EPM1 (ref. 10). Levels of messenger RNA encoded by CST6 were dramatically decreased in patients. A 3' splice site and a stop codon mutation were identified in three families, leaving most mutations uncharacterized. In this study, we report a novel type of disease-causing mutation, an unstable 15- to 18-mer minisatellite repeat expansion in the putative promoter region of the CST6 gene. The mutation accounts for the majority of EPM1 patients worldwide. Haplotype data are compatible with a single ancestral founder mutation. The length of the repeat array differs between chromosomes and families, but changes in repeat number seem to be comparatively rare events.


Cystatins/genetics , Epilepsies, Myoclonic/genetics , Minisatellite Repeats/genetics , Mutation/genetics , Cystatin B , Female , Founder Effect , Humans , Male , Molecular Sequence Data , Polymorphism, Genetic , Promoter Regions, Genetic/genetics , Restriction Mapping
17.
Rev Esp Fisiol ; 53(3): 307-15, 1997 Sep.
Article En | MEDLINE | ID: mdl-9442577

In this study, virion-associated RNA was measured in plasma from twenty six patients in various stages of HIV-1 disease by the additive RT-PCR method. Plasma viral RNA levels were inversely correlated (r = -0.72894) with total CD4+ cell counts and directly (r = 0.86964) with serum titre beta 2-microglobulin in chronically infected patients. This additive RT-PCR is based on a mathematical logistic adjustment of the standard curve and the use of an internal standard identical to the target molecule, which represents a control system for the efficiency of RT-PCR and allows a continuous assessment of the accuracy based on the recovery.


Acquired Immunodeficiency Syndrome/virology , HIV-1/isolation & purification , Polymerase Chain Reaction/methods , Case-Control Studies , HIV-1/genetics , Humans , Logistic Models , RNA, Viral/isolation & purification , Reproducibility of Results , Transcription, Genetic
19.
Hypertension ; 28(1): 98-103, 1996 Jul.
Article En | MEDLINE | ID: mdl-8675271

In the present study, we studied angiotensin II type 1 (AT1) and type 2 (AT2) receptor messengers by quantitative reverse transcriptase-polymerase chain reaction. We examined peripheral blood mononuclear cells from 30 healthy subjects and 50 subjects with primary hypertension, in whom angiotensin I-converting enzyme genotype was determined, before and after 15 days of treatment with different antihypertensive drugs. The medication included a calcium channel antagonist, an angiotensin I-converting enzyme inhibitor, and a beta 1-blocker. We also studied the relationship between AT1 receptor gene expression and biochemical parameters of the renin-angiotensin system. AT1 receptor messenger levels were positively correlated with plasma renin activity in both normotensive and untreated hypertensive subjects. Increases of this messenger and plasma angiotensin II levels were correlated with the D allele in the same individuals. AT1 receptor messenger levels decreased significantly with angiotensin I-converting enzyme inhibitor treatment in subjects with the DD genotype, and a significant decrease was observed in subjects with the II and ID genotypes treated with a calcium antagonist. No changes were observed in mRNA with the beta 1-blocker. We conclude that the AT2 receptor is not expressed in peripheral leukocytes and that AT1 receptor messenger levels vary in relation to angiotensin I-converting enzyme genotype and pharmacological treatment. These results suggest that angiotensin I-converting enzyme genotype may be an important factor when deciding on antihypertensive therapy in individuals with primary hypertension.


Angiotensin II/genetics , Antihypertensive Agents/therapeutic use , Genotype , Hypertension/drug therapy , Hypertension/genetics , Peptidyl-Dipeptidase A/genetics , RNA, Messenger/genetics , Receptors, Angiotensin/genetics , Adrenergic beta-Antagonists/pharmacology , Adrenergic beta-Antagonists/therapeutic use , Adult , Angiotensin-Converting Enzyme Inhibitors/pharmacology , Angiotensin-Converting Enzyme Inhibitors/therapeutic use , Antihypertensive Agents/pharmacology , Base Sequence , Calcium Channel Blockers/pharmacology , Calcium Channel Blockers/therapeutic use , Data Interpretation, Statistical , Female , Genetic Markers , Humans , Male , Middle Aged , Molecular Sequence Data , RNA, Messenger/analysis , Renin-Angiotensin System/drug effects , Renin-Angiotensin System/physiology , Time Factors
20.
J Acquir Immune Defic Syndr Hum Retrovirol ; 12(2): 107-11, 1996 Jun 01.
Article En | MEDLINE | ID: mdl-8680880

SUMMARY: The levels of human immunodeficiency virus type 1 (HIV-1) RNA have been directly quantitated, after an isolation step, in plasma from patients with primary HIV-1 infection by free solution capillary electrophoresis (FSCE) with ultraviolet detection. HIV-1 RNA was detected and quantified at physiological levels by measuring the absorbance by FSCE. All the patients with primary infection showed concentrations in a range of 1.08-1.71 x 10(8) virions/ml of plasma. No signals were observed in seronegative donors. This procedure represents a practical alternative to other methods to quantify HIV-1 RNA and may be useful in assessing the efficiency of antiretroviral agents, especially during the early stage when other conventional viral markers are often negative.


Electrophoresis, Capillary/methods , HIV Infections/virology , HIV-1/isolation & purification , RNA, Viral/blood , Case-Control Studies , Electrophoresis, Capillary/standards , Electrophoresis, Capillary/statistics & numerical data , Evaluation Studies as Topic , HIV Seronegativity , HIV-1/physiology , Humans , RNA, Viral/standards , Reference Standards , Reproducibility of Results , Virus Replication
...